EGFR and neoplasm: Meanwhile, genomic profiling of tumor tissue via next-generation sequencing (NGS) panels identifies driver mutations (e.g., EGFR [11], BRAF [12]) and gene fusions (e.g., ALK [13], ROS1 [13]), enabling selection of small-molecule inhibitors that specifically block oncogenic signaling [14,15].